苯乙酰胺,a-羟基-3,5-二硝基- | 3237-49-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 中文名称: 苯乙酰胺,a-羟基-3,5-二硝基-
• 中文别名: [(2R,3S,4R,5R)-3,4-二羟基-5-(2-氧代-6-硫代-3H-嘌呤-9-基)四氢呋喃-2-基]磷酸二氢甲酯
• 英文名称: 6-Thioxanthine 5'-monophosphate
• 英文别名: [(2R,3S,4R,5R)-3,4-dihydroxy-5-(2-oxo-6-sulfanylidene-3H-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate
• CAS: 3237-49-8
• 化学式: C₁₀H₁₃N₄O₈PS
• 分子量: 380.27
• InChiKey: WMRIOGFRJLQENF-UUOKFMHZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.5
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  208
• 氢给体数：
  6
• 氢受体数：
  10

文献信息

• Method for optimizing thiopurine efficacy and toxicity using mass spectrometry
  申请人：Dervieux Thierry

  公开号：US20060216726A1

  公开（公告）日：2006-09-28

  The present invention relates to methods for optimizing therapeutic efficacy or reducing toxicity in a subject receiving a drug providing 6-thioguanine nucleotide. The methods provide determining 6-thioguanine and 6-methyl-mercaptopurine nucleotide concentration levels using an analytical technique having an ionizing source.

  本发明涉及用于优化接受提供6-硫鸟嘌呤核苷的药物的受试者的治疗效果或减少毒性的方法。该方法提供使用具有电离源的分析技术确定6-硫鸟嘌呤和6-甲基巯基嘌呤核苷浓度水平。
• Methods of disease activity profiling for personalized therapy management
  申请人：NESTEC S.A.

  公开号：US10086072B2

  公开（公告）日：2018-10-02

  The present invention provides methods for personalized therapeutic management of a disease in order to optimize therapy and/or monitor therapeutic efficacy. In particular, the present invention comprises measuring an array of one or a plurality of biomarkers at a plurality of time points over the course of therapy with a therapeutic agent to determine a mucosal healing index for selecting therapy, optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment. In certain instances, the therapeutic agent is a TNFα inhibitor for the treatment of a TNFα-mediated disease or disorder.

  本发明提供了对疾病进行个性化治疗管理的方法，以优化治疗和/或监测疗效。特别是，本发明包括在使用治疗剂治疗过程中的多个时间点测量一个或多个生物标志物阵列，以确定用于选择治疗、优化治疗、降低毒性和/或监测疗效的粘膜愈合指数。在某些情况下，治疗剂是 TNFα 抑制剂，用于治疗 TNFα 介导的疾病或紊乱。
• Assays for the detection of anti-TNF drugs and autoantibodies
  申请人：Nestec S.A.

  公开号：US10386366B2

  公开（公告）日：2019-08-20

  The present invention provides assays for detecting and measuring the presence or level of anti-TNFα drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNFα drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug.

  本发明提供了用于检测和测量样本中抗 TNFα 药物治疗剂和自身抗体的存在或水平的检测方法。本发明适用于优化治疗和监测接受抗 TNFα 药物治疗的患者，以检测抗药物的自身抗体（如 HACA 和/或 HAHA）的存在或水平。
• Methods for prediction of anti-TNFα drug levels and autoantibody formation
  申请人：Prometheus Biosciences, Inc.

  公开号：US10571467B2

  公开（公告）日：2020-02-25

  In some aspects, the present invention provides methods for predicting whether a subject will develop autoantibodies to an anti-TNFα drug during the course of anti-TNFα drug therapy. In other aspects, the present invention provides methods for predicting the level of an anti-TNFα drug in a subject during the course of anti-TNFα drug therapy. Systems for predicting anti-TNFα drug levels and the likelihood of autoantibody formation during the course of anti-TNFα drug therapy are also provided herein. The present invention further provides methods for predicting a clinical outcome (e.g., endoscopic response) of a subject on anti-TNFα drug therapy.

  在某些方面，本发明提供了在抗TNFα药物治疗过程中预测受试者是否会产生抗TNFα药物自身抗体的方法。在其他方面，本发明提供了在抗TNFα药物治疗过程中预测受试者体内抗TNFα药物水平的方法。本发明还提供了在抗TNFα药物治疗过程中预测抗TNFα药物水平和自身抗体形成可能性的系统。本发明进一步提供了预测抗TNFα药物治疗对象临床结果（如内窥镜反应）的方法。
• Assays for detecting neutralizing autoantibodies to biologic therapy
  申请人：Prometheus Biosciences, Inc.

  公开号：US10794906B2

  公开（公告）日：2020-10-06

  The present invention provides assays for detecting and measuring the presence or level of neutralizing and non-neutralizing autoantibodies to biologics such as anti-TNFα drug therapeutics in a sample. The present invention is useful for monitoring the formation of neutralizing and/or non-neutralizing anti-drug antibodies over time while a subject is on biologic therapy. The present invention is also useful for predicting and/or determining the cross-reactivity of neutralizing anti-drug antibodies in a subject's sample with alternative biologic therapies. As such, the present invention provides information for guiding treatment decisions for those subjects receiving therapy with a biologic agent and improves the accuracy of optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment to biologic therapy.

  本发明提供了检测和测量样本中生物制剂（如抗肿瘤坏死因子α药物治疗剂）的中和和非中和自身抗体的存在或水平的检测方法。本发明可用于监测受试者在接受生物制剂治疗期间中和和/或非中和抗药物抗体的形成。本发明还可用于预测和/或确定受试者样本中的中和抗药性抗体与替代生物疗法的交叉反应。因此，本发明为那些接受生物制剂治疗的受试者提供了指导治疗决策的信息，并提高了优化治疗、降低毒性和/或监测生物疗法疗效的准确性。